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Is it possible to claim or refute sputum
eosinophils ≥ 3% in asthmatics with
sufficient accuracy using biomarkers?
Sophie F. Demarche1,2* , Florence N. Schleich1, Virginie A. Paulus1, Monique A. Henket1, Thierry J. Van Hees2
and Renaud E. Louis1
Abstract: The concept of asthma inflammatory phenotypes has proved to be important in predicting response to
inhaled corticosteroids. Induced sputum, which has been pivotal in the development of the concept of inflammatory
phenotypes, is however not widely available. Several studies have proposed to use surrogate exhaled or blood
biomarkers, like fractional exhaled nitric oxide (FENO), blood eosinophils and total serum immunoglobulin E (IgE).
However, taken alone, each of these biomarkers has moderate accuracy to identify sputum eosinophilia. Here,
we propose a new approach based on the likelihood ratio to study which thresholds of these biomarkers, taken
alone or in combination, were able to rule in or rule out sputum eosinophils ≥3%. We showed in a large population
of 869 asthmatics that combining FENO, blood eosinophils and total serum IgE could accurately predict sputum
eosinophils ≥ or <3% in 58% of our population.
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Introduction
Asthma is a heterogeneous airway inflammatory disease.
With the emergence of sputum analysis, the eosinophilic
and non-eosinophilic phenotypes have been described,
which were suggested to have different sensitivities to
inhaled corticosteroids (ICS) [1]. It was indeed shown
that eosinophilic asthmatics responded better to ICS
in terms of symptoms, respiratory function and bron-
chial hyperresponsiveness than their non-eosinophilic
counterparts [2, 3].
Measuring sputum eosinophils in clinical practice is
not applicable to the general population because it is
technically demanding and time-consuming. To over-
come this issue, user-friendly biomarkers like fractional
exhaled nitric oxide (FENO), blood eosinophils and total
serum immunoglobulin E (IgE) have been suggested as
surrogate markers of airway eosinophilic inflammation
[4]. Numerous thresholds for these biomarkers have
been proposed to identify eosinophilic asthmatics [4–8],
which may be confusing for the clinician. Moreover,
each of these biomarkers taken alone has variable and
moderate accuracy [4], that may be enhanced by com-
bining them (like combining FENO and blood eosino-
phils [5]). Despite these efforts, there is currently no
clear recommendation applicable to clinicians in their of-
fice practice to help them identify the eosinophilic status
of their patients using the aforementioned biomarkers.
The purpose of our study was to assess whether several
pragmatic thresholds of FENO, blood eosinophils and
total IgE, taken alone or combined, were able to rule in or
rule out sputum eosinophils ≥3%. In order to answer this
question, we have calculated the likelihood ratio (LR) for
each corresponding threshold or combination of thresh-
olds, on a large database of asthmatic patients. The LR is a
measure of diagnostic accuracy combining both the sensi-
tivity and specificity, which is particularly useful for the
clinician, with values above 10 or below 0.1 allowing to
rule in or rule out the “disease” (i.e. eosinophilic asthma in
this study) with strong evidence [9].
Methods
We conducted a retrospective cross-sectional study on 869
asthmatics of varied severity recruited from the University
Asthma Clinic of Liege, Belgium. Patients were eligible for
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the study if they had a visit with a successful measure of
sputum eosinophils, FENO, blood eosinophils and total
serum IgE (all performed on the same day) between January
2005 and September 2016. The study was approved by
the ethics committee of the University Hospital of Liege
(Ref 2016/276).
Asthma was diagnosed based on typical symptoms
(wheezing, breathlessness, chest tightness, cough) and at
least one of the following criteria: an improvement of
12% and 200 mL in forced expiratory volume in one
second (FEV1) following inhalation of 400 μg salbutamol
or a provocative concentration of methacholine causing
a 20% fall in FEV1 (PC20M) <16 mg/mL. Sputum induc-
tion and processing were performed as previously de-
scribed, using the whole expectorate technique [10]. The
eosinophilic phenotype was defined as a sputum eosino-
phil count ≥3% [11]. FENO was measured at a flow rate
of 50 mL/s (NIOX, Aerocrine, Solna, Sweden). Blood
samples of patients were analysed by the routine labora-
tory of the University Hospital of Liege.
Data were expressed as numbers and percentages for
categorical variables and as median (first and third quar-
tiles) or mean ± standard deviation for continuous vari-
ables. Non-eosinophilic asthmatics were compared to
eosinophilic asthmatics using a Pearson’s chi-squared
test for categorical variables, a Student’s t-test for para-
metric continuous variables, and a Mann-Whitney test
for non-parametric continuous variables. To assess the
ability of FENO, blood eosinophils, total IgE or their
combination to rule in or rule out eosinophilic asthma,
we chose pragmatic thresholds for each biomarker based
on previously published data [4–8], with 2 additional
thresholds to improve the practicality of the tool: 150
blood eosinophils/μL and 500 kU total IgE/L. These
thresholds are presented in Fig. 1. The LR calculation
was performed in two parts. In the first part (presented
in the right side of Fig. 1), we calculated the positive LRs
to assess which threshold(s) was (were) able to rule in
eosinophilic asthma. For each threshold or combination
of thresholds, the positive LR was calculated as follows: %
of eosinophilic asthmatics whose value(s) of the bio-
marker(s) was (were) above the threshold(s)/% of non-
eosinophilic asthmatics whose value(s) of the biomarker(s)
was (were) above the threshold(s). This formula actually
corresponds to: sensitivity/(1-specificity). Positive LR
values above 10 allow to rule in eosinophilic asthma with
strong evidence [9] and are highlighted by dark red in
Fig. 1. In the second part (presented in the left side of
Fig. 1), we calculated the negative LRs to assess which
threshold(s) was (were) able to rule out eosinophilic
asthma (i.e. to rule in non-eosinophilic asthma). For
each threshold or combination of thresholds, the nega-
tive LR was calculated as follows: % of eosinophilic
asthmatics whose value(s) of the biomarker(s) was
(were) below the threshold(s)/% of non-eosinophilic
asthmatics whose value(s) of the biomarker(s) was
(were) below the threshold(s). This formula actually
corresponds to: (1-sensitivity)/specificity. Negative LR
values under 0.1 allow to rule out eosinophilic asthma
(i.e. to rule in non-eosinophilic asthma) with strong evi-
dence [9] and are highlighted by dark blue in Fig. 1.
Positive LRs between 5 and 10, and negative LRs
between 0.1 and 0.2 give moderate evidence [8] to rule
in or rule out eosinophilic asthma, and are only given
in Fig. 1 for information. To ensure the reliability of the
results, only subgroups including at least 20 patients
were considered for the LR calculation. A p value <0.05
was considered statistically significant. Statistical ana-
lysis was done using STATA version 13.0 (Statistical
Software, College Station, TX: StataCorp LP).
Results
Our cohort included 869 patients. Patient characteristics
of the total population and comparison between non-
eosinophilic and eosinophilic asthmatics are shown in
Table 1. The prevalence of eosinophilic asthma was 43%.
Figure 1 represents the strength of the LR for each
threshold of FENO, blood eosinophils and total IgE,
taken alone or in combination. LRs above 10 give strong
evidence to rule in eosinophilic asthma and are
highlighted by dark red in Fig. 1 while LRs below 0.1
give strong evidence to rule out eosinophilic asthma (i.e.
to rule in non-eosinophilic asthma) and are highlighted
by dark blue in Fig. 1 [9]. The LRs for a single biomarker
can be found in Fig. 1 where the values of the other two
biomarkers are not taken into account. Likewise, the
LRs for combinations of two biomarkers are found in
the grid where the value of the third biomarker is not
taken into account. For example, a patient with <20 ppb
of FENO has not a strong prediction of non-eosinophilic
asthma (0.2 < LR < 5), while a patient with <20 ppb of
FENO and <100 blood eosinophils/μL has a strong pre-
diction of non-eosinophilic asthma (LR < 0.1).
If we focus on clinically relevant LRs for the bio-
markers taken alone, a value of FENO >80 ppb was asso-
ciated with a LR above 10 (Fig. 1). In our population,
10% (89/869) of patients had a FENO >80 ppb, of whom
79 (89%) were actually eosinophilic. Likewise, a value of
blood eosinophils >1000 cells/μL was associated with a
LR above 10. In our study, 2% (20/869) of patients had
>1000 blood eosinophils/μL, of whom 18 (90%) were
actually eosinophilic. This threshold was not shown in
Fig. 1 because the subgroup it determined only in-
cluded 20 patients and a combination with other bio-
markers would necessarily lead to <20 patients per
group. No threshold of FENO or blood eosinophils
used as single biomarkers was associated with a LR
below 0.1. As for total IgE, no threshold was able to
Demarche et al. Respiratory Research  (2017) 18:133 Page 2 of 6
reach a LR above 10 or below 0.1. When considering
FENO, blood eosinophils or their combination without
using total IgE (corresponding to the upper left panel
and the upper right panel of Fig. 1), 45% of the population
(393/869) was included in at least one category associated
with a LR above 10 or below 0.1. Of these 393 patients, 352
(90%) were properly classified into eosinophilic or non-
eosinophilic asthma. Finally, when considering FENO,
blood eosinophils, total IgE or their combination
(corresponding to the entire Fig. 1), 58% of our popula-
tion (506/869) was included in at least one category as-
sociated with a LR above 10 or below 0.1. Of these 506
patients, 440 (87%) were properly classified into eosino-
philic or non-eosinophilic asthma. The number of subjects
with a strong evidence of eosinophilic or non-eosinophilic
asthma was therefore significantly increased from 393 to
Fig. 1 Representation of the strength of the likelihood ratio to predict non-eosinophilic (left panel) or eosinophilic (right panel) asthma according
to several thresholds of FENO, blood eosinophils, total IgE or their combination. Each square of the Figure represents a subgroup of at least 20
patients. Abbreviations: Blood eos blood eosinophils, FENO fractional exhaled nitric oxide, IgE immunoglobulin E
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506 patients when IgE levels were taken into account
(p < 0.0001 using the McNemar test), while keeping an ac-
curacy of nearly 90%.
In asthmatics untreated with ICS (N = 314), 189 pa-
tients (60%) were included in at least one category with
a LR above 10 or below 0.1 in Fig. 1, of whom 169 (89%)
were correctly classified. In asthmatics treated with ICS
(N = 555), 317 patients (57%) were included in at least
one category with a LR above 10 or below 0.1, of whom
271 (85%) were correctly classified. The proportion of
patients with a strong evidence of eosinophilic or non-
eosinophilic asthma and the correctness of the tool were
not statistically different between patients untreated and
treated with ICS (p = 0.38 and p = 0.20, respectively).
Discussion
In our study, we showed that FENO and blood eosinophils
used as single biomarkers were able to accurately predict
sputum eosinophils ≥3% in a very small proportion of pa-
tients (10% and 2%, respectively), while IgE levels taken
alone were unable to accurately predict the eosinophilic
status. Overall, these results are consistent with previous
studies reporting that these biomarkers are not sufficiently
Table 1 Patient characteristics
Total population Non-eosinophilic asthmatics (NEA) Eosinophilic asthmatics (EA) p (NEA vs EA)
N 869 495 374 -
Women, N (%) 505 (58) 314 (63) 191 (51) <0.001
Age, years 49 (35–61) 46 (33–59) 51 (38–63) <0.001
BMI, kg/m2 26.2 ± 5.2 26.3 ± 5.3 26.2 ± 5.0 0.96
Atopy, N (%) 482 (56) 251 (51) 231 (62) 0.001
Smoking status, N (%)
Non-smokers 457 (53) 262 (53) 195 (52) 0.049
Current smokers 187 (21) 118 (24) 69 (18)
Ex-smokers 225 (26) 115 (23) 110 (29)
FEV1, % predicted 83.6 ± 20.6 86.6 ± 19.8 79.6 ± 20.9 <0.001
FEV1/FVC, % 72.6 ± 11.1 74.4 ± 10.6 70.1 ± 11.3 <0.001
PC20M, mg/mLa 2.9 (0.7–13.0) 3.7 (0.9–15.0) 1.8 (0.5–9.8) <0.001
Reversibility, % 7 (2–12) 6 (2–11) 8 (3–14) <0.001
ACQ score 2.0 ± 1.2 1.9 ± 1.1 2.2 ± 1.3 <0.001
AQLQ score 4.5 ± 1.4 4.5 ± 1.3 4.5 ± 1.4 0.38
FENO, ppb 23 (13–45) 17 (12–29) 41 (21–72) <0.001
Sputum eosinophils, % of non-squamous cells 1.8 (0.2–10.8) 0.2 (0.0–1.0) 13.2 (6.5–35.0) <0.001
Sputum neutrophils, % of non-squamous cells 53 (28–76) 64 (39–84) 41 (22–59) <0.001
Total serum IgE, kU/L 121 (37–328) 79 (23–227) 200 (80–472) <0.001
Blood eosinophils, cells/μL 188 (109–328) 137 (80–217) 290 (189–507) <0.001
Blood neutrophils, cells/μL 4068 (3150–5402) 4034 (3058–5498) 4078 (3228–5312) 0.58
ICS category, N (%)
Steroid naive 314 (36) 204 (41) 110 (30) 0.003
Low doseb 126 (15) 71 (14) 55 (15)
Medium doseb 182 (21) 97 (20) 85 (23)
High doseb 242 (28) 121 (25) 121 (33)
OCS therapy, N (%) 62 (7) 30 (6) 32 (9) 0.16
LABA, N (%) 530 (61) 279 (56) 251 (67) 0.001
LTRA, N (%) 220 (25) 130 (26) 90 (24) 0.46
Theophylline, N (%) 25 (3) 17 (3) 8 (2) 0.26
aData available for 493 patients of the total population: 312 non-eosinophilic patients and 181 eosinophilic patients
bLow dose ICS: ≤ 500 μg per day; medium dose ICS: >500–1000 μg per day; high dose ICS: >1000 μg per day beclomethasone dipropionate - chlorofluorocarbon
Abbreviations: ACQ asthma control questionnaire, AQLQ asthma quality of life Questionnaire, BMI body mass index, FENO fractional exhaled nitric oxide, FEV1
forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, IgE immunoglobulin E, LABA long-acting β2-agonist, LTRA leukotriene receptor
antagonist, OCS oral corticosteroid, PC20M provocative concentration of methacholine causing a 20% fall in FEV1
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good predictors of the airway eosinophilic status when
used as single surrogate markers [4, 12].
Hastie et al. showed that combining FENO and blood
eosinophils did not accurately predict the eosinophilic
phenotype in asthmatic patients, with an accuracy (defined
as the percentage of subjects correctly classified by the test
as having or not having eosinophilic asthma) of 55% [12].
When using FENO and blood eosinophils, our data show
that we can only achieve a satisfactory prediction in 45% of
patients, which is not very different from what Hastie et al.
reported. We also found that measuring total IgE may be
of interest as the proportion of asthmatics accurately pre-
dicted rose from 45 to 58% of the population, which sup-
ports the idea that combining biomarkers is useful [13].
Our results highlight the fact that these three surro-
gate markers are not able to entirely replace the sputum
analysis to determine the eosinophilic status of patients.
However, we still believe that the use of these bio-
markers is valuable in routine clinical practice. Their
measure is easy to perform, well standardised, less costly
than sputum analysis, and their results are rapidly avail-
able. Therefore, we may suggest measuring these bio-
markers in asthmatic patients in whom the practitioner
wants to know the eosinophilic phenotype. For the 58% of
patients identified by the tool as having a strong evidence
of eosinophilic or non-eosinophilic asthma, a sputum in-
duction might be spared. However, for the remaining 42%
of patients, a sputum induction would be recommended
in a dedicated centre to identify their eosinophilic status.
One limitation of our study is its retrospective design.
Moreover, the accuracy of the tool in Fig. 1 should also
be studied in other centres performing sputum in
asthmatic patients to assess its generalisability (external
validity) [14]. Nevertheless, a strength of our study is
that our asthmatic population encompassed the all
spectrum of severity and our grid may therefore be ap-
plicable to a majority of patients seen in clinical practice.
Although ICS are known to impact sputum and blood
eosinophils as well as FENO [15], our data show that the
tool is suitable for asthmatic patients regardless of treat-
ment with ICS. Therefore, the Figure could be printed
and kept in the pocket of the practitioner as a companion
tool to profile the eosinophilic phenotype in asthma.
In conclusion, combining exhaled breath and blood
biomarkers to identify airway eosinophilia appears to be
a valuable attitude in clinical practice in around 60% of
patients, leaving the remaining 40% with uncertain eo-
sinophilic status, which should be investigated by a spu-
tum analysis.
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